Synthesis and biological evaluation of chromone derivatives against triple-negative breast cancer cells

被引:2
|
作者
Islam, Rajibul [1 ]
Yan, Mock Phooi [1 ]
Yen, Khor Poh [2 ]
Rasol, Nurulfazlina Edayah [3 ,4 ]
Meng, Chan Kok [5 ]
Wai, Lam Kok [1 ]
机构
[1] Univ Kebangsaan Malaysia, Fac Pharm, Ctr Drug & Herbal Dev, Kuala Lumpur 50300, Malaysia
[2] Univ Kuala Lumpur, Royal Coll Med Perak, Fac Pharm & Hlth Sci, Ipoh 30450, Perak, Malaysia
[3] Univ Teknol MARA, Atta ur Rahman Inst Nat Prod Discovery, Puncak Alam Campus, Bandar Puncak Alam 42300, Selangor, Malaysia
[4] Univ Teknol MARA, Fac Appl Sci, Shah Alam 40450, Selangor, Malaysia
[5] Univ Kebangsaan Malaysia, Fac Hlth Sci, Ctr Toxicol & Hlth Risk Studies, Jalan Raja MudaAbdul Aziz, Kuala Lumpur 50300, Malaysia
关键词
Triple-negative breast cancer; Chromone; Anticancer; Multi-kinase inhibitor; INHIBITOR LY294002; KINASE; DOXORUBICIN; DESIGN; DEATH; PROLIFERATION; OPTIMIZATION; CHEMOTHERAPY; EXPRESSION; EFFICIENT;
D O I
10.1007/s00044-023-03048-4
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
This study described the bioactivity and the structure-activity relationship (SAR) of newly synthesized chromone derivatives against triple-negative breast cancer (TNBC) MDA-MB-231 cells. Among the compounds tested, C8 exerted a growth inhibitory effect on the TNBC-derived MDA-MB-231 cells with an IC50 value of 11.71 +/- 0.79 mu M. Results showed that it could promote apoptosis, sensitize TNBC MDA-MB-231 cells to doxorubicin (Dox) and inhibit multiple kinase activities with higher selectivity against PIM1 and PIM2 kinases. Molecular docking results revealed compound C8 engaged in several critical interactions with the important residues in PIM1 and PIM2 binding sites. This suggests that compound C8 possessed anticancer activity on TNBC cells potentially mediated by inhibition of multiple tyrosine kinases and kinases involved in cell-cycle regulation.
引用
收藏
页码:884 / 898
页数:15
相关论文
共 50 条
  • [31] Tackling the Biological Diversity in Early Triple-Negative Breast Cancer
    Oliveira, Mafalda
    Saura, Cristina
    BREAST CARE, 2020, 15 (03) : 205 - 206
  • [32] Design, synthesis and biological evaluation of new SIRT3 activators for the treatment of triple-negative breast cancer
    Huang, Guichan
    Wang, Hailing
    Zhao, Xi
    Wang, Chen
    Zhang, Jin
    Yao, Dahong
    Li, Chenyang
    BIOORGANIC & MEDICINAL CHEMISTRY, 2025, 118
  • [33] Preclinical evaluation of the AR inhibitor enzalutamide in triple-negative breast cancer cells
    Caiazza, Francesco
    Murray, Alyson
    Madden, Stephen F.
    Synnott, Naoise C.
    Ryan, Elizabeth J.
    O'Donovan, Norma
    Crown, John
    Duffy, Michael J.
    ENDOCRINE-RELATED CANCER, 2016, 23 (04) : 323 - 334
  • [34] Targeting Cancer Stem Cells in Triple-Negative Breast Cancer
    Park, So-Yeon
    Choi, Jang-Hyun
    Nam, Jeong-Seok
    CANCERS, 2019, 11 (07)
  • [35] Evaluation of Local Injection of Bevacizumab against Triple-Negative Breast Cancer Xenograft Tumors
    Jiang, Xin
    Zhang, Qiao-Li
    Liu, Tie-Gang
    Zhao, Wei-Peng
    Yang, Ming
    Wang, Li-Na
    Sun, Wei-Liang
    Pan, Lin
    Luo, Ai-Ping
    Huang, Jin-Chang
    Gu, Xiao-Hong
    CURRENT PHARMACEUTICAL DESIGN, 2019, 25 (08) : 862 - 870
  • [36] Asporin: The protective wall against triple-negative breast cancer
    Blomme, Arnaud
    Cusumano, Pino
    Peulen, Olivier
    Bellahcene, Akeila
    Castronovo, Vincent
    Turtoi, Andrei
    M S-MEDECINE SCIENCES, 2016, 32 (11): : 1019 - 1022
  • [37] Rational combination therapy against triple-negative breast cancer
    Al-Ejeh, F.
    Miranda, M.
    Simpson, P. T.
    Chenevix-Trench, G.
    Lakhani, S. R.
    Khanna, K. K.
    CANCER RESEARCH, 2012, 72
  • [38] Ruthenium metallodendrimer against triple-negative breast cancer in mice
    Michlewska, Sylwia
    Wojkowska, Dagmara
    Watala, Cezary
    Skiba, Elzbieta
    Ortega, Paula
    de la Mata, Francisco Javier
    Bryszewska, Maria
    Ionov, Maksim
    NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2023, 53
  • [39] Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer
    Chen, Luxi
    Long, Chao
    Nguyen, Jennifer
    Kumar, Dhiraj
    Lee, Jiyong
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2018, 28 (03) : 420 - 424
  • [40] A novel (+)-dehydroabietylamine derivative shows activity against triple-negative breast cancer cells
    Gautam, Lekh Nath Sharma
    Ling, Taotao
    Rivas, Fatima
    CANCER RESEARCH, 2016, 76